1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Sun Pharma Introduces a Novel Treatment Starizo in India

24 Aug 2024
Admin
News Article

Sun Pharma Introduces a Novel Treatment Starizo in India

Sun Pharma introduces a novel treatment, Starizo in India for acute bacterial skin and skin structure infections

Overview

Sun Pharmaceutical Industries Limited announced that it has launched tedizolid phosphate tablets 200 mg in India under the brand name “Starizo”.

Starizo for Infection

Starizo (tedizolid phosphate) is a novel, oxazolidinone-class antibacterial, used to treat acute bacterial skin and skin structure infection (ABSSSI).

Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise tedizolid phosphate in India.

Statement from Sun Pharma

“Drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) causing ABSSSIs, are more challenging to treat due to the limited availability of effective treatment options in hospitals. With Starizo, we are introducing a treatment option which is effective and has the convenience of once-a-day dosing”, said Kirti Ganorkar, CEO - India business, Sun Pharma.
“At Sun Pharma, it has always been our endeavour to introduce innovative medicines that help improve the quality of life of patients,” he added.

Skin and Soft Tissue Infections

Skin and soft tissue infections are the most common type of infections constituting, around 29-32% of all infections in 2018-2019 in India.
The treatment of ABSSSI is further complicated with associated comorbidities such as diabetes, obesity, renal and hepatic dysfunction in these patients.

S. Aureus Infections

The incidence of invasive S. aureus infections has increased over the past decades and is associated with poor outcomes and high mortality rates.
S. aureus is responsible for almost one-third of ABSSSIs, with MRSA accounting for a large proportion of these.
MRSA rates in India have been increasing each year from 28.4% in 2016 to 42.6% in 2021 (S. aureus infections).
Drug-resistant bacteria such as MRSA causing ABSSSIs, are more challenging to treat due to the limited availability of effective antibiotics.

Starizo Treatment

Starizo (tedizolid phosphate) is a once-a-day oral treatment for six days compared to the current standard of care which has to be given twice daily for 10-14 days.
Starizo (tedizolid phosphate) has demonstrated activity against gram-positive organisms, including MRSA.
Starizo (tedizolid) provides the advantage of reduced frequency and duration of drug administration.
Starizo requires no dose adjustment in the elderly, patients with hepatic or renal impairment and patients on haemodialysis.

Tedizolid phosphate is sold in India under a licensing agreement with Merck Sharp & Dohme Singapore Trading Pte. Ltd.

About Sun Pharma

Sun Pharma is a leading global specialty generics company with presence in Innovative products, generics and consumer healthcare products.
It is the largest pharmaceutical company in India and is a leading generic company in the US as well as global emerging markets.